Wave Life Sciences Ltd. Ordinary Shares - WVE STOCK NEWS

Wave Life Sciences (WVE) announced positive results from its Phase 1b/2a study of WVE-N531 in Duchenne muscular dystrophy (DMD). The study showed a mean exon skipping rate of 53% and a tissue concentration of 42 micrograms/gram after six weeks of biweekly dosing at 10 mg/kg. While dystrophin levels were below detection limits, safety and tolerability were confirmed with only mild adverse events. The company plans to evaluate next steps for WVE-N531 following this encouraging proof-of-concept data.

Wave Life Sciences announces a strategic collaboration with GSK to advance oligonucleotide therapeutics, including WVE-006 for alpha-1 antitrypsin deficiency (AATD). The partnership involves an upfront payment of $170 million, comprising $120 million in cash and $50 million in equity, with potential milestone and royalty earnings exceeding $500 million. Wave will leverage its PRISM platform alongside GSK's expertise to progress multiple programs over an initial four-year term, enhancing its pipeline and extending its cash runway into 2025.

Wave Life Sciences announced key developments in its third quarter 2022 report, highlighting progress in clinical trials for Huntington’s disease (WVE-003) and Duchenne muscular dystrophy (WVE-N531). The SELECT-HD trial showed safe, well-tolerated doses and a reduction in mutant huntingtin protein. WVE-006 was selected for alpha-1 antitrypsin deficiency, with CTA submissions expected in 2023. Financially, the company reported a net loss of $39 million and a significant revenue drop to $0.3 million, mainly due to prior collaboration amendments. Cash on hand is $122 million, expected to last through 2023.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will participate in an analyst-led fireside chat at the Stifel 2022 Healthcare Conference in New York City on November 16, 2022, at 3:35 p.m. ET. This event focuses on the company's commitment to developing genetic medicines for devastating diseases. A live webcast of the discussion will be available on the company’s Investor Relations page, with replays accessible for a limited time post-event.

Wave Life Sciences (Nasdaq: WVE) announced a conference call scheduled for 8:30 a.m. ET on November 10, 2022, to discuss its Q3 2022 financial results and provide a business update. The call will be accessible via the company’s investor relations webpage. Wave Life Sciences is a clinical-stage genetic medicines company focused on developing treatments for severe diseases using its proprietary PRISM platform for drug development. The archived call will also be available post-event.

Wave Life Sciences Ltd. (Nasdaq: WVE) announced its participation in upcoming scientific conferences to showcase advancements in oligonucleotide chemistry and RNA editing. This includes preclinical data for WVE-006, targeting alpha-1 antitrypsin deficiency, which is presented for the first time. The presentations at the Oligonucleotide Therapeutics Society and European Society of Gene & Cell Therapy meetings will emphasize the company's proprietary discoveries and drug development capabilities.

Wave Life Sciences highlighted its advanced candidate, WVE-006, for treating alpha-1 antitrypsin deficiency (AATD) during a recent virtual event. The RNA editing program aims to correct genetic mutations and restore functional protein levels. Preclinical data show a significant increase in AAT protein production and functional activity. Clinical trial applications for WVE-006 are expected to be submitted in 2023. Wave is also exploring broader applications for its AIMers technology beyond AATD, potentially impacting multiple diseases.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that CEO Paul Bolno will participate in an analyst-led fireside chat at Chardan’s 6th Annual Genetic Medicines Conference on October 4, 2022, at 3:15 p.m. ET in New York City. A live webcast of the event will be accessible on the company's Investor Relations page, with a replay available for a limited time afterward. Wave Life Sciences focuses on developing innovative treatments for genetically defined diseases through its proprietary PRISM platform.

Wave Life Sciences Ltd. announces positive results from the SELECT-HD Phase 1b/2a clinical trial of WVE-003, a candidate for treating Huntington’s disease. Single doses of 30 or 60 mg led to a mean reduction of 22% in mutant huntingtin protein levels in cerebrospinal fluid, with a median reduction of 30%. The treatment was reportedly well-tolerated, with no serious adverse events. Wave plans to expand the dosing cohorts and has early data supporting allele-selective knockdown of the harmful protein. Further updates are expected in 1H 2023.